AKYA Share Price Performance
US$1.29
-1.25 (-49.21%)
50.0% undervalued intrinsic discount
US$2.58
Fair Value
Price US$1.29
AnalystConsensusTarget US$2.58
Fair ValueUS$2.58
Share Pricen/a
Akoya Biosciences, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
AKYA Community Narratives
AN
Fair Value US$2.58 50.0% undervalued intrinsic discount
Expanding Reagent Offerings And Diagnostics Will Widen Platform Adoption
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Expanding Reagent Offerings And Diagnostics Will Widen Platform Adoption
Key Takeaways Expansion of reagent offerings and diagnostics partnerships aim to boost revenue growth and improve margins significantly. Operational efficiencies and strategic collaborations enhance platform utilization, positioning Akoya for sustainable growth and profitability.Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$2.58
50.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
9.69% p.a.
Profit Margin
12.89%
Future PE
12.73x
Price in 2028
US$3.46
Trending Discussion
Recently Updated Narratives
AN
Expanding Reagent Offerings And Diagnostics Will Widen Platform Adoption
Fair Value: US$2.58 50.0% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Akoya Biosciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- -0.95
- 61.74%
- -59.45%
- -1,298.8%
About AKYA
- Founded
- 2015
- Employees
- 205
- CEO
- WebsiteView website
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
